New York, NY – November 17, 2021 – Ortoli Rosenstadt LLP, a New York full-service international law firm, today announced that it represented Mainz BioMed N.V., a German-based company that develops market-ready molecular genetic diagnostic solutions for life-threatening conditions such as cancer, as it became publicly listed in the U.S. market. Mainz BioMed’s ordinary shares began trading on the Nasdaq Capital Market under the ticker symbol “MYNZ” on November 5, 2021.
“We would like to congratulate Mainz BioMed for beginning its journey on the Nasdaq Capital Market,” commented Partner William Rosenstadt. “As a firm, we are proud to have helped them reach this milestone, and we believe that it will make for a wonderful public company.”
The Ortoli Rosenstadt LLP team included Partners William Rosenstadt and Jason Ye, Counsel Tim Dockery, and Associate Shawn Chen.
